Current medical treatment for tuberculosis

British Medical Journal

Volumn 325, Issue 7375, 2002, Pages 1282-1286

  Chan, Edward D ^a   Iseman, Michael D ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; LINEZOLID; PHENYTOIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMATE; RIFAMPICIN; RIFATER; STREPTOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANOREXIA; DEVELOPING COUNTRY; DIARRHEA; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG TOLERANCE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERSENSITIVITY REACTION; HYPERURICEMIA; INDUSTRIALIZATION; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEPHROTOXICITY; NEURITIS; OPTIC NERVE DISEASE; OTOTOXICITY; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RASH; REVIEW; SEIZURE; SPUTUM CULTURE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUBERCULOSIS; VESTIBULAR DISORDER;

EID: 0037202688     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.325.7375.1282     Document Type: Review

References (38)

1. Raviglione MC, Snider DEJ, Kochi A. Global epidemiology of tuberculosis: Morbidity and mortality of a worldwide epidemic. JAMA 1995;273:220-6.
2. WHO Report 2002: Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva: World Health Organization, 2002.
3. Burwen DR, Bloch AB, Griffin LD, Ciesielski CA, Stern HA, Onorato IM. National trends in the concurrence of tuberculosis and acquired immunodeficiency syndrome. Arch Intern Med 1995;155:1281-6.
4. Cantwell MF, Snider DEJ, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1992;272:535-9.
5. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970;20:810-4.
6. Mitchison DA. Basic concepts in the chemotherapy of tuberculosis. In: Gangadharam PRJ, Jenkins PA, eds. Mycobacteria. II. Chemotherapy. New York: Chapman & Hall, 1998:15-50.
7. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: The results up to 24 months. Tubercle 1979;60:201-10.
8. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: Results at 30 months. Am Rev Respir Dis 1991;143:700-6.
9. Ass JB Jr, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994;149:1359-74.
10. Barnes PF, Leedom JM, Chan LS, Wong SF, Shah J, Vachon LA, et al. Predictors of short-term prognosis in patients with pulmonary tuberculosis. J Infect Dis 1988;158:366-71.
11. Iseman MD. A Clinician's Guide to Tuberculosis. Baltimore: Lippincott, Williams & Wilkins, 1999.
12. Sbarbaro JA, Sbarbaro JB. Compliance and supervision of chemotherapy of tuberculosis. Sem Respir Infect 1994;9:120-7.
13. Burman WJ, Cohn DL, Rietmeijer CA, Judson FN, Sbarbaro JA, Reves RR. Short-term incarceration for the management of noncompliance with tuberculosis treatment. Chest 1997;112:57-62.
14. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: A twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990;112:407-15.
15. Chaulk CP, Friedman M, Dunning R. Modeling the epidemiology and economics of directly observed therapy in Baltimore. Int J Tuberc Lung Dis 2000;4:201-7.
16. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998;279:943-8.
17. Nardell EA. Beyond four drugs: Public health policy and the treatment of the individual patient with tuberculosis [editorial]. Am Rev Respir Dis 1993;148:2-5.
18. Burman WJ, Dalton CB, Cohn DL, Butler JRG, Reves RR. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest 1997;112:63-70.
19. Moore RD, Chaulk CP, Griffiths R, Cavalcante S, Chaisson RE. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996;154:1013-9.
20. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States. 2000. Atlanta, GA: Centers for Disease Control and Prevention, 2000.
21. Nunn P, Kibuga D, Gathna S, Brindle R, Imalingat A, Wasunna K, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 sero-positive patients treated for tuberculosis. Lancet 1991;337:627-30.
22. Corbett EL, Steketee RW, ter Kuile FO, Latif AS, Kamali A, Hayes RJ. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 2002;359:2177-87.
23. Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996;30:919-25.
24. Centers for Disease Control. Clinical update: Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR 1996;45:921-5.
25. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2000;49:185-9.
26. Wagner KR, Bishai WR. Issues in the treatment of Mycobacterium tuberculosis in patients with human immunodeficiency virus infection. AIDS 2001;15(suppl):203-12S.
27. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998;158:157-61.
28. Pulido F, Pena J-M, Rubio R, Moreno S, Gonzalez J, Guijarro C, et al. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997;157:227-32.
29. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: Common errors and their association with the acquisition of drug resistance. JAMA 1993;270:65-8.
30. Passannante MR, Gallagher CT, Reichman LB. Preventive therapy for contacts of multidrug-resistant tuberculosis: A Delphi survey. Chest 1994;106:431-4.
31. Sbarbaro JA, Iseman MD, Crowle AJ. Combined effect of pyrazinamide and ofloxacin within the human macrophage. Tuberc Lung Dis 1996;77:491-5.
32. American Thoracic Society update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations -United States, 2001. Am J Respir Crit Care Med 2001;164:1319-20.
33. Horn DL, Hewlett D, Alfalla C, Peterson S, Opal SM. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994;330:1241.
34. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997;24:1264-5.
35. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161(suppl):221-478
36. Iseman MD. Tuberculosis therapy: (Past), present and future. Eur Respir J 2002 (in press).
37. Durban Immunotherapy Trial Group. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: A randomised controlled trial. Lancet 1999;354:116-9.
38. McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000;406:735-8.